ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2760

Assessment of Inflammatory Back Pain and Axial Spondyloarthritis in Brazil

Sonia Lima1, Rita Menin2, Rejane Vieira3, Antonio Ximenes4, Valderilio Azevedo5, Claudia Suzuki6 and Flavia Heringer6, 1Faculdade de Medicina do ABC, São Paulo, Brazil, 2AV. JUSCELINO K. DE OLIVEIRA,, Famerp, Sao Jose Rio Preto, Brazil, 3Hospital Geral de Fortaleza, Fortaleza, Brazil, 4CIP- Centro Internacional de Pesquisa, Goiânia, Brazil, 5Federal University of Parana and Edumed Health Research Centerand Biotech, Curitiba, Brazil, 6AbbVie Farmacêutica Ltda., São Paulo, Brazil

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: chronic low back pain, diagnosis and spondylarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The concept of inflammatory back pain (IBP) was proposed in association with ankylosing spondylitis (AS), one prototype of Spondyloarthritis (SpA), more than 60 years ago. Spondyloarthritis (SpA) comprises several rheumatic diseases. Although several criteria sets have been developed, the diagnosis of SpA remains challenging. This study aims to evaluate the frequency of inflammatory back pain (IBP) among Brazilian subjects with chronic back pain (CBP), and to describe the results of rheumatologic evaluation based on the axial SpA classification criteria from the Assessment of Spondyloarthritis International Society (ASAS).

Methods:  This was an observational study with retrospective (phase 1) and one-month prospective (phase 2) data collection. Medical records of subjects 18-60 years old, with onset of back pain at age <40 years, and with CBP (pain almost daily ≥3 months), were included in phase 1. Subjects with at least one ASAS screening parameter for IBP were contacted by phone, and confirmed IBP cases were invited to phase 2. At phase 2 visit 1, HLA-B27 and C-reactive protein (CRP) were requested. At phase 2 visit 2, the fulfilment of the ASAS classification criteria for axial SpA was verified. Frequency of IBP among subjects with CBP starting before the age of 40 years was estimated. For subjects included in phase 2, the proportions of positive HLA-B27, AS and non-radiographic axial SpA (nrAxSpA) were calculated.

Results:  A total of 363 records of subjects with CBP were reviewed from five sites. Based on medical records and phone contact, 130 subjects had IBP confirmed (35.8%, 95%CI: 30.9-40.7%). From IBP population, only 52 subjects accepted to participate in phase 2. Mean age was 38.8±11.43 years, 64% were female, 85% professionally active, and 14% had family history of IBP related conditions. Time since CBP onset was 12.3±10.09 years and no subject had a prior diagnosis of SpA. Among the 50 patients that completed visit 2, 14% had positive HLA-B27, 82% had lesions of the sacroiliac joint assessed by MRI, 16% had abnormal clinically significant CRP results, and 10% had grade 3-4 lesions assessed by X-ray. The proportions of AS and nrAxSpA cases were 46% and 26%, respectively by ASAS classification criteria.

Conclusion:  More than one third of the CBP subjects with onset <40 years had IBP by ASAS criteria. Of notice, subjects with a positive HLA-B27 test did not have prior diagnosis of axial SpA. The results in this Brazilian population suggest that patients with IBP may be under diagnosed, delaying their treatment, and that women may seek more for medical care than men. An eventual selection bias cannot be excluded.


Disclosure: S. Lima, Pfizer Inc, 5,AbbVie, 5,Bristol-Myers Squibb, 5,Janssen Pharmaceutica Product, L.P., 5,AbbVie, 2; R. Menin, Pfizer Inc, 5,Eli Lilly and Company, 5,AbbVie, 2; R. Vieira, AbbVIe, 2; A. Ximenes, AbbVie, 2; V. Azevedo, AbbVie, 2,AbbVie, 5,Pfizer Inc, 5,Roche Pharmaceuticals, 5,Bristol-Myers Squibb, 5,Celltrion, 5,Janssen Pharmaceutica Product, L.P., 5,Sanofi-Aventis Pharmaceutical, 5,Novartis Pharmaceutical Corporation, 5,AstraZeneca, 5,UCB, 5,AbbVie, 8,Janssen Pharmaceutica Product, L.P., 8,Bristol-Myers Squibb, 8,Pfizer Inc, 8,MerckSerono, 8,AstraZeneca, 8; C. Suzuki, AbbVie, 3; F. Heringer, AbbVie, 3.

To cite this abstract in AMA style:

Lima S, Menin R, Vieira R, Ximenes A, Azevedo V, Suzuki C, Heringer F. Assessment of Inflammatory Back Pain and Axial Spondyloarthritis in Brazil [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/assessment-of-inflammatory-back-pain-and-axial-spondyloarthritis-in-brazil/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-inflammatory-back-pain-and-axial-spondyloarthritis-in-brazil/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology